Biotech Alchemab Therapeutics has extended its series A financing with a £25 million ($34 million) investment from the British Business Bank – the Bank’s largest investment in a life sciences company to date.  

The company says the funding will enable it to build its clinical pipeline and grow its antibody dataset to more than a billion sequences. 

Alchemab’s Resiliome platform uses complex AI derived algorithms to identify naturally occurring antibodies present in humans with unusual resilience to a range of hard-to-treat diseases. 

This investment builds on the success of the company’s first asset, ATLX-1282 – a first-in-class antibody therapeutic in clinical development for amyotrophic lateral sclerosis (ALS) which was licensed to Eli Lilly. 

The additional funding brings Alchemab’s total Series A investment to date to £109 million. It will enable the company to enhance its antibody database from 500 million to a billion antibody sequences and advance additional candidates into clinical development. 

Dr Jane Osbourn, CEO and Co-Founder of Alchemab, said: “We are delighted that British Business Bank has recognised the importance of enabling Alchemab to grow and thrive here in the UK. This investment provides further validation of the sustainable, long-term potential of our drug discovery platform and will enable us to further accelerate our pipeline of first-in-class antibody therapeutics for conditions with significant unmet need.” 

Charlotte Lawrence, Managing Director of Direct Equity at British Business Bank added: “Alchemab sits at the cutting edge of UK scientific capability, integrating deep sequencing and lab-based validation to harness the body’s natural defences against disease. This landmark £25m investment demonstrates our commitment to providing the long-term capital necessary for the UK’s most innovative biotech firms to advance complex pipelines in the UK.”